Additional Benefits of Combining GLP-1 Receptor Agonist Use With Lifestyle Modification

GLP-1 receptor agonists have largely contributed to revolutionising pharmacological therapy of type 2 diabetes. They are among the most potent glucose-lowering agents, while also eliciting bodyweight reduction—an effect that, before their introduction, was reached only through lifestyle intervention. Moreover, and more importantly, these medications have shown unprecedented cardiorenal protection in both randomised controlled trials1 and real-world studies.2 A further confirmation of these beneficial effects is reported by Xuan-Mai T Nguyen and colleagues in this issue of The Lancet Diabetes & Endocrinology.